Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Abstract Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and
effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a …

Background Polyclonal convalescent plasma may be obtained from donors who have
recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in …

Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …

Importance There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in
patients hospitalized with COVID-19. Objective To determine the safety and efficacy of CCP …

Quantitative or qualitative differences in immunity may drive clinical severity in COVID-19.
Although longitudinal studies to record the course of immunological changes are ample …

BACKGROUND Evidence supporting convalescent plasma (CP), one of the first
investigational treatments for coronavirus disease 2019 (COVID-19), has been inconclusive …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent
plasma (CCP) to treat hospitalized patients. Over 500,000 patients were treated with CCP …

Convalescent plasma has been used worldwide to treat patients hospitalized with
coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global …